Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
| ▸ | CTSD | P07339 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26616556 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2HPGDLMNAPKMHDAC1 | |
| SCHEMBL6446379 | 0.91 | ALDH1A1 (0.56) | SMN1; SMN2HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL5711363 | 0.91 | ALDH1A1 (0.56) | SMN1; SMN2HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL6136522 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2HPGDLMNAPKMHDAC1 | |
| SCHEMBL14997395 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2HPGDLMNAPKMHDAC1 | |
| SCHEMBL6136527 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2HPGDLMNAPKMHDAC1 | |
| SCHEMBL8241511 | 0.84 | SMN1; SMN2 (0.74) | SMN1; SMN2HPGDLMNAPKMHDAC1 | |
| SCHEMBL26710742 | 0.82 | CCR1 (0.60) | SMN1; SMN2HPGDLMNAPKMHDAC1 | |
| SCHEMBL9501718 | 0.82 | CCR1 (0.60) | SMN1; SMN2HPGDLMNAPKMHDAC1 | |
| SCHEMBL4412844 | 0.81 | POLB (0.59) | HPGDALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288559-A1 | PREP BINDING LIGANDS | POLKU THERAPEUTICS OY (FI) | 2025-09-18 | — | — | US | disclosed |
| EP-4514781-A1 | PREP BINDING LIGANDS | Polku Therapeutics OY (FI) | 2025-03-05 | — | — | EP | disclosed |
| CN-119451944-A | PREP binding ligands | 珀尔库治疗有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2023209191-A1 | PREP BINDING LIGANDS | UNIVERSITY OF HELSINKI (FI) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209191-A1 | PREP BINDING LIGANDS | UNIVERSITY OF HELSINKI (FI) | 2023-11-02 | — | — | WO | disclosed |
| US-10202418-B2 | Hydroxy-ethylene derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2019-02-12 | — | — | US | disclosed |
| US-20160145297-A1 | HYDROXY-ETHYLENE DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160145297-A1 | HYDROXY-ETHYLENE DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2016-05-26 | — | — | US | disclosed |
| WO-2014198372-A1 | HYDROXY-ETHYLENE DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2014-12-18 | — | — | WO | disclosed |
| EP-0232849-B1 | PYRROLIDINEAMIDE DERIVATIVE OF ACYLAMINO ACID, PHARMACEUTICAL COMPOSITION AND USE | SUNTORY LIMITED (JP) | 1993-05-05 | — | — | EP | disclosed |
| US-5198458-A | Pyrrolidineamide derivatives of acylamino acid and pharmaceutical composition containing the same | SUNTORY LIMITED (JP) | 1993-03-30 | — | — | US | disclosed |
| US-4826870-A | CURING AMNESIA | SUNTORY LIMITED (JP) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202418-B2 | Hydroxy-ethylene derivatives for the treatment of arthrosis | CTSD, CTSE, CTSB | SMN1; SMN2 4293/4885HPGD 45/4885LMNA 2218/4885 |
| US-20160145297-A1 | HYDROXY-ETHYLENE DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | CTSD, CTSE, CTSB | SMN1; SMN2 4293/4885HPGD 45/4885LMNA 2218/4885 |
| US-20250288559-A1 | PREP BINDING LIGANDS | PREP, ERAP2, CTSA | SMN1; SMN2 3319/4885HPGD 3255/4885LMNA 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.